Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus subtilis de111
- Development stage
- Unknown
- Lead developer
- Archer Daniels Midland
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus subtilis DE111 is a branded, clinically-studied strain of the probiotic bacterium *Bacillus subtilis*. As a spore-forming organism, it is highly resistant to heat and stomach acid, allowing it to survive transit through the upper gastrointestinal tract and germinate in the small intestine. [4, 5, 19] Clinical trials and studies have investigated its use for supporting digestive health, including improving bowel regularity and alleviating occasional constipation or diarrhea. [NCT04083521, 18] It is also studied for its ability to modulate the immune system, exhibiting anti-inflammatory effects and supporting a healthy immune response. [2, 3, 7] Further research suggests it may help maintain healthy cholesterol levels, aid in the digestion of nutrients like gluten, and support a healthy gut microbiome by crowding out pathogenic bacteria. [NCT04489810, 8, 10] DE111 was developed by Deerland Probiotics & Enzymes, which is now part of ADM, and is used as an ingredient in various dietary supplements, foods, and beverages. [6, 9, 11, 15]
- Brand names
- DE111DE-111DE 111
- Other names
- 枯草芽孢杆菌DE111
Beyond the preview
Go deeper on bacillus subtilis de111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus subtilis de111.